Skip to Main Content

Author Details

Kevan C Herold
Yale University
1983
266
73
PMIDPaper TitleJournal TitlePublished Year
36860908Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis.J Endocr Soc2023
37667106High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment.Diabetologia2023
37708415Hydroxychloroquine in Stage 1 Type 1 Diabetes.Diabetes Care2023
37586769ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis.J Immunother Cancer2023
37890101Response to Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005-1013.Diabetes Care2023
37878676Immune responses to gut bacteria associated with time to diagnosis and clinical response to T cell-directed therapy for type 1 diabetes prevention.Sci Transl Med2023
37502867Latent EBV impairs immune cell signaling and enhances the efficacy of anti-CD3 mAb in Type 1 Diabetes.medRxiv2023
37607392Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function.Diabetes Care2023
37254311Incidence, characteristics, risk factors and outcomes of diabetic ketoacidosis in COVID-19 patients: Comparison with influenza and pre-pandemic data.Diabetes Obes Metab2023
37349129Response to "<i>NLRC5</i> germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng.J Immunother Cancer2023
37079384HSV-2 triggers upregulation of MALAT1 in CD4+ T cells and promotes HIV latency reversal.J Clin Invest2023
37000695Phenotypes Associated With Zones Defined by Area Under the Curve Glucose and C-peptide in a Population With Islet Autoantibodies.Diabetes Care2023
36857969Incidence of new-onset in-hospital and persistent diabetes in COVID-19 patients: comparison with influenza.EBioMedicine2023
36920087Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.Diabetes Care2023
36741943Barriers to Screening: An Analysis of Factors Impacting Screening for Type 1 Diabetes Prevention Trials.J Endocr Soc2023
36898736Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors.J Immunother Cancer2023
36730530CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study.Diabetes Care2023
35316839Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective.Diabetes2022
35350573Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function.Front Oncol2022
35499468Indirect and Direct Effects of SARS-CoV-2 on Human Pancreatic Islets.Diabetes2022
35388005Citrullination of glucokinase is linked to autoimmune diabetes.Nat Commun2022
36150059Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes.Diabetes Care2022
36074833COVID-19 and children.Science2022
35998266The Transition From a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk.Diabetes Care2022
35925682Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes.JCI Insight2022
36326757Persistence of β-Cell Responsiveness for Over Two Years in Autoantibody-Positive Children With Marked Metabolic Impairment at Screening.Diabetes Care2022
36257528RAGE antagonism with azeliragon improves xenograft rejection by T cells in humanized mice.Clin Immunol2022
35881836The β-Cell in Type 1 Diabetes Pathogenesis: A Victim of Circumstances or an Instigator of Tragic Events?Diabetes2022
36219765Erratum. Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes. Diabetes Care 2022;45:2189-2201.Diabetes Care2022
32886542Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors.Annu Rev Med2021
33881515Advances in Type 1 Diabetes Prediction Using Islet Autoantibodies: Beyond a Simple Count.Endocr Rev2021
33822777Natural mucosal barriers and COVID-19 in children.JCI Insight2021
33640598Adverse events induced by immune checkpoint inhibitors.Curr Opin Immunol2021
33558698Quantifying the effect of experimental perturbations at single-cell resolution.Nat Biotechnol2021
33529163A little help from residual β cells has long-lasting clinical benefits.J Clin Invest2021
33658358Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.Sci Transl Med2021
34551936The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes.Diabetes2021
34747368IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes.JCI Insight2021
34417463Tet2 Controls the Responses of β cells to Inflammation in Autoimmune Diabetes.Nat Commun2021
34326232Immunotherapy: Building a bridge to a cure for type 1 diabetes.Science2021
34324441The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.JCI Insight2021
31601695PET Imaging of Pancreatic Dopamine D<sub>2</sub> and D<sub>3</sub> Receptor Density with <sup>11</sup>C-(+)-PHNO in Type 1 Diabetes.J Nucl Med2020
33778814Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors.Clin Oncol Case Rep2020
31913467Circulating Unmethylated Insulin DNA As a Biomarker of Human Beta Cell Death: A Multi-laboratory Assay Comparison.J Clin Endocrinol Metab2020
32003110Early and late C-peptide responses during oral glucose tolerance testing are oppositely predictive of type 1 diabetes in autoantibody-positive individuals.Diabetes Obes Metab2020
32833543Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes.Diabetes Technol Ther2020
32573927Exenatide extended release in patients with type 1 diabetes with and without residual insulin production.Diabetes Obes Metab2020
32958614Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients.Sci Transl Med2020
32986722The receptor for advanced glycation endproducts (RAGE) modulates T cell signaling.PLoS One2020
32439823Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials.Diabetes2020
  • 1 - 50 of 266

Recommended Authors

Ya??ma L Lightfoot
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 1
Thomas A Packard
J. David Gladstone Institutesgrid.249878.8
Career Start Year 2011
Number of shared co-authors 0
Klara R Klein
University of North Carolina School of Medicine
Career Start Year 2010
Number of shared co-authors 1
Howard R Seay
College of Medicine, Diabetes Institute, University of Florida
Career Start Year 2007
Number of shared co-authors 10
Magnus Isaksson
Uppsala University
Career Start Year 2007
Number of shared co-authors 0
Alice E Wiedeman
Center for Translational Immunology, Benaroya Research Institute at Virginia Mason
Career Start Year 2007
Number of shared co-authors 13
Marc Veldhoen
Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa
Career Start Year 2005
Number of shared co-authors 0
Shari Messinger
University of Miami Miller School of Medicine
Career Start Year 2004
Number of shared co-authors 3
Johnna D Wesley
Novo Nordisk Research Center Seattle, Inc.
Career Start Year 2003
Number of shared co-authors 3
Andrew Wang
Yale University School of Medicine
Career Start Year 2001
Number of shared co-authors 4
Nayyar Iqbal
Pondicherry Institute of Medical Sciences
Career Start Year 1998
Number of shared co-authors 1
Michael R Rickels
Hospital of the University of Pennsylvania
Career Start Year 1995
Number of shared co-authors 5
David J Huss
Biogen Inc.
Career Start Year 1995
Number of shared co-authors 0
Francesca Fallarino
University of Perugia
Career Start Year 1995
Number of shared co-authors 0
Hui-Chen Hsu
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham
Career Start Year 1993
Number of shared co-authors 1
Chander Raman
University of Alabama at Birmingham
Career Start Year 1990
Number of shared co-authors 0
Teresa P DiLorenzo
Universidad Cardenal Herrera-CEU, CEU Universities
Career Start Year 1989
Number of shared co-authors 3
Michael J Clare-Salzler
University of Florida College of Medicine
Career Start Year 1989
Number of shared co-authors 5
Qi Wu
University of Michigan Medical School
Career Start Year 1989
Number of shared co-authors 0
Laura Santambrogio
Weill Cornell School of Medicine
Career Start Year 1988
Number of shared co-authors 0
Ursula Grohmann
University of Perugia
Career Start Year 1988
Number of shared co-authors 0
Jose Oberholzer
University of Virginia Health System
Career Start Year 1988
Number of shared co-authors 1
Maura Rossetti
University of California Los Angeles
Career Start Year 1986
Number of shared co-authors 1
Su M Metcalfe
University of Cambridge Clinical School, LIFNanoRx Ltd
Career Start Year 1984
Number of shared co-authors 0
Penelope A Morel
University of Pittsburgh
Career Start Year 1982
Number of shared co-authors 0
Fernando Ovalle
Comprehensive Diabetes Center, University of Alabama at Birmingham
Career Start Year 1981
Number of shared co-authors 2
Jonathan Braun
Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center
Career Start Year 1975
Number of shared co-authors 2
Merrill Eric Gershwin
Allergy and Clinical Immunology, University of California at Davis
Career Start Year 1967
Number of shared co-authors 2
Shigeo Koyasu
RIKEN Center for Integrative Medical Sciences (IMS)
Career Start Year 1966
Number of shared co-authors 0
David W Scott
University of British Columbia
Career Start Year 1965
Number of shared co-authors 0

Collaborators

Carla J Greenbaum
Center for Interventional Immunology, Benaroya Research Institute at Virginia Mason
Co-authored papers 28
Jeffrey P Krischer
Health Informatics Institute, University of South Florida
Co-authored papers 18
Sarah Alice Long
Center for Translational Immunology, Benaroya Research Institute at Virginia Mason
Co-authored papers 9
Craig A Beam
Homer Stryker MD School of Medicine, Western Michigan University
Co-authored papers 8
Mario R Ehlers
Clinical Trials Group
Co-authored papers 7
Harriet M Kluger
Yale School of Medicine
Co-authored papers 7
Peter S Linsley
8Benaroya Research Institute
Co-authored papers 7
Brygida Bisikirska
Columbia University
Co-authored papers 6
Mark S Anderson
Diabetes Center, University of California san francisco
Co-authored papers 6
Richard E Carson
Yale University
Co-authored papers 5
Gerald T Nepom
Wash Benaroya Research Institute at Virginia Mason
Co-authored papers 5
Benjamin Glaser
Co-authored papers 5
Cate Speake
Center for Interventional Immunology, Benaroya Research Institute at Virginia Mason
Co-authored papers 5
Jane H Buckner
Center for Translational Immunology, Benaroya Research Institute at Virginia Mason
Co-authored papers 5
Deborah J Lenschow
Co-authored papers 4
Clive Wasserfall
Co-authored papers 4
Henry Rodriguez
Office of Cancer Clinical Proteomics Research, National Cancer Institute
Co-authored papers 4
Elisavet Serti
The Henry Jackson Foundation.
Co-authored papers 3
Kristina M Harris
University of California san francisco
Co-authored papers 3
Chris Cotsapas
Co-authored papers 3
David A Hafler
Yale School of Medicine, Yale School of Public Health
Co-authored papers 3
James Dziura
Yale School of Medicine
Co-authored papers 3
Steven M Willi
Children's Hospital of Philadelphia
Co-authored papers 3
Noha Lim
Co-authored papers 3
Richard Torres
Yale University School of Medicine
Co-authored papers 2
Jeremy Luban
Co-authored papers 2
Matthew J Dufort
Center for Systems Immunology, Benaroya Research Institute Seattle
Co-authored papers 2
Stephen S Rich
Co-authored papers 2
Leonard D Shultz
The Jackson Laboratory Cancer Center
Co-authored papers 2
Marshall Alan Permutt
Washington University School of Medicine
Co-authored papers 2
Release 1.2